According to a guidance document from the American Society of Health-System Pharmacists (ASHP), smart infusion pump optimization requires an ongoing, multidisciplinary governance process to ensure that Dose Error Reduction Software (DERS) and associated drug libraries remain current, clinically appropriate, and consistently used. The guidance recommends establishing a Smart Pump Governance Team led by pharmacy and/or nursing representatives with participation from pharmacists, nurses, providers, and other relevant stakeholders to routinely evaluate smart pump performance and recommend system changes. All smart pump profile areas should be reviewed at least annually, with a comprehensive review of drug dosing limits conducted quarterly according to a facility-defined schedule, and additional reviews performed as needed following medication errors or other safety concerns. At a minimum, routine reviews should evaluate the most frequently used medications, formulary updates, overall compliance with dosing limits, and compliance within individual pump profiles, while also considering successful and unsuccessful alerts, patient outliers, medication errors, relevant safety recommendations, and bedside audit findings when available. Recommended drug library or dosing-limit changes should undergo pharmacist review, incorporate nursing input, and receive approval through an interdisciplinary medication safety or equivalent committee before implementation. The guidance also recommends communicating updates to end users through strategies such as computerized prescriber order entry alerts, safety huddles, departmental communications, pump safety initiatives, and summary materials. Following implementation, the governance team should continue monitoring frequently used medications, previously implemented changes, infusion- or pump-related medication incidents, and case-based safety events to determine whether the changes improved smart pump use and identify opportunities for further optimization. [1]
The 2020 Institute for Safe Medication Practices (ISMP) guidelines were developed from literature review, reported medication errors, practitioner surveys, and expert consensus. Recommendations emphasize consistent use of dose error-reduction systems (DERS) for medication and intravenous fluid infusions, with compliance targets of at least 95%; pumps that default to DERS programming; and interdisciplinary management of drug libraries with updates at least quarterly. Library optimization includes standardized medication names, dosing units, and concentrations; population-specific profiles; upper and lower soft and hard limits; restricted custom concentrations; and independently verified library changes. Organizations should review pump data at least quarterly, including compliance, alerts, overrides, reprogramming, and library update completion, and use findings to revise libraries, reduce nuisance alerts, improve workflows, and guide education. [2]
Bidirectional interoperability with the electronic health record (EHR) is recommended to support automatic programming and documentation, with reliable wireless coverage, barcode medication administration, aligned infusion parameters, and testing of orders and library changes. Workflow recommendations include staff competency assessments, tubing tracing, safer secondary infusion management, and double checks for selected high-alert infusions. Pediatric and neonatal considerations include profiles and limits tailored to population, acuity, and weight; verification of dosing weight; correct transfer of weight-based orders; and assessment of small-volume, low-flow syringe infusion workflows. Oncology is represented in the surveys, and the guidelines address correct transfer of body surface area-based dosing, but separate pediatric or oncology effectiveness outcomes are not reported. The document acknowledges limited controlled clinical trial evidence for individual safety practices. [2]
The 2021 Joint Commission Sentinel Event Alert 63 addresses smart infusion pump optimization through DERS, using published literature and safety guidance rather than an original intervention study. Identified barriers include library omissions and bypasses, alert fatigue, pump availability, programming complexity, and usability problems. A cited 2016 study attributed approximately 10% of infusion administration errors or policy violations to bypassing the smart pump or drug library. Recommended strategies include multidisciplinary oversight; independently checked library entries; standardized names, units, and concentrations across systems; reliable updates to every pump; restricted custom concentrations; and population-specific dosing limits. The alert also recommends initial training and annual competency assessments, routine DERS use, and monitoring of alerts, overrides, workarounds, errors, and near misses to identify needed changes to limits and processes. [3]
When organizational capabilities permit, the alert recommends bidirectional pump-EHR integration to reduce manual programming errors by transferring concentration, dose, rate, and weight or body surface area directly from the EHR. It also addresses staffing, distractions, lighting, confusing controls, cybersecurity, and downtime procedures. Pediatric and oncology recommendations specifically include tailored library subsets with appropriate doses and administration limits, plus verification of the correct profile during transfers; separate population-specific outcomes are not reported. The Joint Commission emphasizes that technology alone cannot ensure safe medication management and clarifies that DERS use is suggested practice rather than a requirement of a Joint Commission standard. [3]
A scope review by Alamer et al. comprehensively examined literature from January 2000 to November 2021 to evaluate the impact of smart infusion pump technology in healthcare. The review focused on assessing both the benefits and limitations associated with smart pumps, with particular attention to their ability to reduce parenteral medication errors. The review synthesized data regarding smart pump efficacy, adverse event cases, compliance issues, and strategies to mitigate associated challenges, thereby providing a broad understanding of the technological integration and its clinical implications. The results highlighted that smart pumps equipped with dose error reduction software (DERS) and comprehensive drug libraries significantly decrease infusion-related medication errors, including incorrect dosing and rate programming. For instance, one study cited reported an 80% reduction in infusion errors, while another identified over 1,100 errors prevented in an ICU setting, thereby potentially averting serious adverse events. However, the review also identified notable challenges such as frequent delays in drug library updates, low compliance with drug library usage, and the high override rates of soft alerts—issues that contribute to alert fatigue and risk mitigation failure. Strategies to improve outcomes included enhancing real-time monitoring of drug library compliance, tailored drug library adjustments to reduce unnecessary alerts, and comprehensive user training. The review highlights the importance of integrating smart pumps with hospital information systems and advocated innovations like auto-programming and streamlined device design to enhance usability and safety further. [4]
A 2022 investigation evaluated the impact of a comprehensive review and revision of the Dose Error Reduction Software (DERS) library specifically tailored for hematology/oncology within a quaternary hospital setting in Australia. A multidisciplinary working group, including hematology and oncology nurses, physicians, pharmacists, DERS experts, and vendor representatives, convened multiple times between February and April 2018 to scrutinize 71 medications. Adjustments encompassed dosing limits, infusion rates, and concentrations aligned with updated institutional chemotherapy protocols and emerging treatments, including new chemotherapy agents and supportive medications. After iterative testing and institutional governance approval, 91 modifications were implemented addressing unnecessary soft alerts and aligning infusions with current clinical practice. Compliance with the DERS library was monitored using vendor-supplied Continuous Quality Improvement (CQI) software, which aggregated pump alert data and infusion records to allow granular monthly analysis. Post-review data collected from June to November 2018 demonstrated an increase in compliance with DERS use from 81.5% to 87.3% in the hematology/oncology setting, although this did not reach statistical significance (p= 0.257). Crucially, nursing staff satisfaction measured via electronic surveys improved significantly; the proportion reporting that the library met their requirements very or extremely well rose from 46.7% to 85.7% (p<0.05), and overall satisfaction increased from 83.3% to 92.8% (p<0.05). Analysis of near-miss events, defined as doses exceeding 10 times the upper limit, decreased from two to zero following the review, indicating enhanced safety. Furthermore, the number of alerts triggered by doses or parameters outside the library limits notably declined primarily due to a reduction in nuisance soft alerts related to fluid rates. [5]
A 2025 scoping review examined literature from January 2000 to September 2024 concerning intravenous smart pump (IVSP) alarms, with an emphasis on air-in-line (AIL) alarms in oncology care. A total of 37 full-text studies were included for analysis. The reviewed evidence primarily consisted of retrospective observational studies, quality improvement projects, and descriptive analyses, with a notable absence of randomized controlled trials. The findings revealed that AIL alarms constitute a significant portion of IVSP alarms (ranging from approximately 3% to nearly 10% in various settings) with a substantial impact on nursing workflow and patient experience. Evidence indicated that many AIL alarms are nonactionable or nuisance alarms, contributing to alarm fatigue, increased nursing workload, and treatment delays. Nurses frequently rated AIL alarms as disruptive and low in clinical usefulness, with each alarm requiring an average of five minutes to resolve, cumulatively amounting to extensive time expenditure. The review highlighted that causes of AIL alarms include both preventable factors, such as improper priming technique or failure to remove air from lines, and nonpreventable factors related to fluid properties or infusion system design. Patient perspectives underscored the negative impact of frequent, loud alarms on comfort and anxiety, particularly during prolonged outpatient oncology infusions noted to average over two hours. [6]
A 2026 single-center quality-improvement and practice implementation initiative was conducted at a tertiary hospital’s oncology and hematology infusion units to enhance intravenous chemotherapy administration safety using parameterised smart infusion pumps governed by a clinical pharmacist-led drug library. The intervention involved creating a structured and validated drug library encompassing 57 antineoplastic agents, with drug-specific infusion-time windows, locked hard limits on infusion rates and durations, and mandatory prompts for administration requirements such as in-line filtration and light protection. The implementation included multidisciplinary collaboration between clinical pharmacists, physicians, and nursing leadership, supported by structured staff training, standardized workflows, and job aids. Over a 12-month period post-implementation, approximately 17,000 chemotherapy days and 40,000 infusions were assessed using pump alert logs and clinical pharmacist review to identify administration discrepancies. During this evaluation, 26 clinically meaningful near-miss administration discrepancies were intercepted before infusion initiation, equating to 0.15 discrepancies per 100 chemotherapy days. The majority (69.2%) of these related to attempted faster-than-protocol infusion rates, with others involving prolonged infusion durations, omission of mandatory in-line filters, or failure to apply light-protective measures. No hard-limit overrides were permitted, ensuring all unsafe programming attempts were blocked. The smart pump system also yielded operational efficiencies by reducing manual programming steps, halving the mean programming time per infusion from approximately 60 seconds to 30 seconds. This translated into an estimated nursing time saving of about one hour per day across a typical workload of 120 chemotherapy infusions, allowing reallocation of time to direct patient care activities. Semi-annual governance ensured ongoing library validation, protocol alignment, and alert review to maintain safety and minimize alert fatigue. Collectively, these results demonstrate that pharmacist-led parameterised smart infusion pumps can standardize chemotherapy administration, reduce high-risk programming errors, and support a proactive medication-safety culture in high-volume oncology settings. [7]